Compositions of descarboethoxyloratadine
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
1. A pharmaceutical composition which comprises 0.1 to 10 mg of descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , which is adapted for oral administration.
3. The pharmaceutical composition of claim 1 , which is solid.
4. The pharmaceutical composition of claim 3 , which is in the form of capsule or tablet.
5. The pharmaceutical composition of claim 1 , wherein the carrier is selected from the group consisting of microcrystalline cellulose, starch, silicon dioxide, magnesium stearate, lactose, and a combination thereof.
6. The pharmaceutical composition of claim 5 , wherein the carrier comprises microcrystalline cellulose.
7. The pharmaceutical composition of claim 5 , wherein the carrier comprises starch.
8. The pharmaceutical composition of claim 5 , wherein the carrier comprises silicon dioxide.
9. The pharmaceutical composition of claim 5 , wherein the carrier comprises magnesium stearate.
10. The pharmaceutical composition of claim 5 , wherein the carrier comprises lactose.
11. A pharmaceutical composition comprising: a) 0.1 mg to 10 mg descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof; b) microcrystalline cellulose; and c) starch.
12. The pharmaceutical composition of claim 11 , which further comprises silicon dioxide.